Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
24.59
33.06
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Deferred Income Tax
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Deferred Income Tax Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Deferred Income Tax | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
|
Deferred Income Tax
ÂĄ656m
|
CAGR 3-Years
30%
|
CAGR 5-Years
20%
|
CAGR 10-Years
71%
|
||
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Deferred Income Tax
ÂĄ255m
|
CAGR 3-Years
28%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Deferred Income Tax
ÂĄ22.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-6%
|
||
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Deferred Income Tax
ÂĄ85.1m
|
CAGR 3-Years
65%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
||
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Deferred Income Tax
ÂĄ91.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
||
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Deferred Income Tax
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, a leading player in China's pharmaceutical industry, stands out for its robust portfolio of products and a commitment to innovation. Founded in 1997 and headquartered in the bustling city of Guangzhou, the company has carved out a significant market presence through its diverse offerings, which include traditional Chinese medicines, chemical pharmaceuticals, and healthcare products. With a strong focus on research and development, Baiyunshan invests heavily in modernizing its production processes and expanding its product lineup, positioning itself well to capitalize on the growing demand for healthcare solutions in China and beyond. Its strategic partnerships and distribution capabilities further enhance its competitive edge, making it not just a manufacturer, but a trusted provider within the healthcare ecosystem. Investors looking at Guangzhou Baiyunshan should note the company’s impressive financial trajectory, characterized by consistent revenue growth and healthy profit margins. The pharmaceutical sector in China is poised for expansion due to an aging population and increasing health awareness, factors that bode well for Baiyunshan's future. The firm’s proactive approach to regulatory compliance and quality assurance has earned it a solid reputation with both consumers and industry stakeholders. As the company continues to enhance its research capabilities and expand its market reach, it represents a compelling opportunity for investors seeking exposure to the burgeoning Chinese pharmaceutical market. With a seasoned management team at the helm and a clear growth strategy, Guangzhou Baiyunshan is not just navigating the complexities of the pharmaceutical landscape; it is poised to thrive within it.
See Also
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Deferred Income Tax?
Deferred Income Tax
656m
CNY
Based on the financial report for Jun 30, 2024, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Deferred Income Tax amounts to 656m CNY.
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
71%
Over the last year, the Deferred Income Tax growth was 1%. The average annual Deferred Income Tax growth rates for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd have been 30% over the past three years , 20% over the past five years , and 71% over the past ten years .